Financing channel feed – Endpoints News

Financing channel feed

Lilly Asia Ventures co-leads $100M+ round for Chinese biotech and its late-stage lupus drug

6 years ago

Ahead of US IPO, Legend Biotech adds $150M, top-tier investors to back CAR-T pipeline

6 years ago

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

6 years ago

Investing in the time of coronavirus: the good, the bad and the hopeful, as biotech VC firms close funds worth $3B

6 years ago

Dynacure secures $55M as their Ionis-developed drug moves into clinic

6 years ago

Stepping out alongside ARCH's record raise, Flagship adds a $1.1B monster fund of its own

6 years ago

ARCH chief Bob Nelsen has $1.5B to prove 2 simple points: ‘We’re in the most innovative time ever’ and investors are staying

6 years ago

‘There was a growing weariness’: Rushing against a pandemic clock, Aspen Neuroscience secures $70M Series A

6 years ago

ITeos nabs $125M as they prep Keytruda combination trial — if Covid-19 will let them

6 years ago

A quiver of arrows for immune disorders: Pandion scores $80M in fresh funding

6 years ago

Can a pair of top AveXis alumni steer a new gene therapy upstart to R&D glory? 3 VCs bet $60M on it

6 years ago

Undeterred by a pandemic, Gilde Healthcare raises their largest fund yet

6 years ago

Unfazed by disruptions, Cowen's investment arm backs AM-Pharma's $176M pivotal plan around lethal condition

6 years ago

David Hallal bags another whopper round, looking to recruit more cell and gene therapy upstarts to ElevateBio BaseCamp

6 years ago

A Singapore VC raises $200M for a new round, but will Covid-19 prevent it from raising the rest?

6 years ago

Coupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world

6 years ago

SutroVax lands another $100M+ in upstart quest against Pfizer’s blockbuster Prevnar 13

6 years ago

Kallyope lands $112 million Series C to ride the gut-brain axis for another 3 years

6 years ago

A key player behind 2 multibillion-dollar biotech M&A deals is back in the startup business

6 years ago

InnoCare IPO oversubscribed 300x as Hong Kong investors turned to biotech amid runoff

6 years ago

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

6 years ago

The big C: The dealmakers, dollars and diseases that have transformed the Chinese biopharma market

6 years ago

Flagship’s Sigilon grabs $80M to bring Robert Langer cell therapy tech into the clinic

6 years ago

Partnered with Gilead and Sanofi, protein degradation specialist Nurix bags $120M to chart its own clinical path

6 years ago

First page Previous page 100 101 102103104 105 106 Next page Last page